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EVIDENCE TOWARDS A NOVEL APPROACH TO 
 
HEPATITIS C VIRUS TESTING IN RESOURCE-LIMITED SETTINGS 
 
J. MORGAN FREIMAN 
ABSTRACT 
 
RATIONALE:  A low cost point of care test (POCT) to diagnose hepatitis C virus 
(HCV) viremia could be a critical step toward HCV elimination. The aim of this 
study is to inform the limit of detection (LOD) for an affordable POC test. 
METHODS: This study analyzed a convenience sample of cross-sectional HCV 
testing data from reference laboratories and clinical research studies in 9 
countries. Participants of all ages with quantified HCV viremia were included. We 
analyzed the distribution of HCV viral load for the first detectable HCV RNA 
available, and derived the clinical sensitivity for a POCT with an LOD of 3 log 
IU/mL. Bivariate and multivariate analyses were then performed to identify 
demographic and clinical characteristics associated with low-level viremia (< 3 
log IU/mL). 
RESULTS: The dataset included 53,295 participants from Cambodia, Canada, 
Cameroon, Georgia, Indonesia, Malaysia, Pakistan, Thailand, and Vietnam. Log 
HCV RNA was normally distributed, and ≥ 3 log IU/mL corresponded with clinical 
sensitivity of 98%. Neither HIV co-infection nor cirrhosis were significantly 
associated with low-level viremia, whereas bivariate analyses showed increased 
odds of 2.47 (95% CI 2.04, 2.99) for low-level HCV RNA among those ≤ 30 years 
old compared to those > 30, and an OR of 1.17 (1.02, 1.34) among females 
	   v 
compared to males. Stepwise multivariate regression found no significant 
confounding. 
CONCLUSION: In this global dataset, a POCT with a LOD of 3 log IU/mL would 
identify 98% of chronic HCV infections. The increase OR among those ≤ 30 
years old year olds is likely explained by a greater frequency among younger 
persons of recent infection, where fluctuating viremia is well described. A POCT 
for HCV that could identify persons with 3 log IU/mL or greater would likely 
facilitate affordable product development and expand the reach of HCV testing in 
resource-limited settings.  
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I: Summary: 
 
Hepatitis C Virus (HCV) is a deadly but curable disease that disproportionately 
affects people in resource-limited-settings. Despite highly effective and tolerable 
treatment, HCV remains a leading cause of death worldwide.  This is in part 
because access to curative treatment is limited, but even more because only a 
fraction of those with disease have been tested and even fewer are aware of 
their diagnosis, as many are lost to follow-up between testing steps.  Many 
instead present after symptoms develop, and they may in the interim 
unknowingly transmit the infection to others.  This is a health inequity for which 
improving testing capacity in resource-limited-settings is paramount.   
 
This study suggests that in 98% of patients with chronic HCV, the amount of 
circulating virus is at least 100 times higher than the lowest level current 
confirmatory tests are capable of detecting. Thus, it is realistic to propose that a 
simpler and potentially less expensive test might be developed that could detect 
the majority of infected persons. In this study, I propose to investigate the clinical 
associations between demographic characteristics of patients with HCV and low-
level viremia to determine whether some groups might be more likely to be 
missed by such a test.  
 
 
II: Background: 
 
The World Health Organization (WHO) defined goals towards the 
	  	  
2 
elimination of viral hepatitis C (HCV) by 2030 calling for a 90% reduction in HCV 
transmission, and a 65% reduction in HCV-related mortality 1,2. HCV prevention, 
increased HCV testing, and access to affordable treatment are critical parts of 
their strategy. Increasing availability of direct acting antiviral agents at 
substantially reduced prices3 should secure access to curative treatment, but 
solutions have not been proposed to address the feasibility of expanding testing, 
especially in remote areas which lack access to centralized laboratory facilities. 
For this reason, the 2016 WHO testing guidance calls for innovations in 
confirmatory testing technology, and research to inform testing approaches in 
resource-limited settings4.  
Approximately 15-25% of persons infected with HCV will clear the virus 
without treatment4, thus the diagnosis of chronic HCV requires two-steps. 
Serologic screening with HCV antibody to test for exposure followed by 
confirmatory testing for active viremia with either a nucleic acid test (NAT) for 
ribonucleic acid (RNA) or core antigen. Confirmatory testing is key to identifying 
those with chronic infection who would be considered for treatment. These tests 
are expensive, and they require advanced diagnostic laboratory facilities. A low-
cost test that could be performed in a single step at the point-of-care (POC) could 
streamline care and improve outcomes 5. 
To consider a POC test for real-world implementation, it must meet WHO 
prequalification standards. Presently there is no evidence to inform the 
prequalification criteria for a POC HCV confirmatory test, and thus they are held 
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to the same standards as NAT. NAT assays can quantify as little as 12 
international units per milliliter, roughly 1 log IU/mL, of circulating HCV virus in a 
venous sample with reliable analytic performance across the six major HCV 
genotypes 6. However, NAT requires electricity, water, refrigerated reagents and 
trained technicians to perform proper amplification. A POC assay cannot employ 
the same amplification step. As a result, most POC confirmatory tests in 
development at this time 7,8 cannot achieve the sensitivity and specificity 
equivalent to current confirmatory tests, but instead reach a limit of detection 
roughly (LOD) 100 times higher.  
Further, an important consideration for the use of a POCT is whether there 
are specific subpopulations among those with chronic HCV that reliably have a 
low-level of viremia and higher risk for false negative test results.  One study 
found significantly lower levels of circulating HCV RNA among those with end-
stage or decompensated cirrhosis when compared to those without cirrhosis.9 
This is likely because the virus requires healthy liver cells to replicate. Another 
study found no significant association between viral load magnitude and HIV co-
infection, age, or sex, though very few participants had HIV.10 Circulating viremia 
among different HCV genotypes also does not appear to be significant.11  
My first hypothesis is that a POCT that detects HCV RNA LOD equal to 3 
log IU/ml (1,000 IU/mL) will maintain >97% clinical sensitivity for diagnosing 
chronic HCV among those with and without HIV co-infection. My second 
hypothesis is that there will be an association with HCV RNA < 3 log IU/mL and 
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cirrhosis, but the magnitude of HCV viremia will not be associated with human 
immunodeficiency virus (HIV) co-infection, age, sex, HCV genotype, or country of 
testing. 
To test these hypotheses, I assembled data from cohorts of HCV infected 
patients around the world to develop a robust dataset with sample distributions of 
the six major HCV genotypes, a spectrum of liver fibrosis stages, and prevalence 
of HIV co-infections. The broad geographic distribution of the cohort is important 
to capture a wide variety of genotypes which differ by region and country, and is 
also intended to incorporate data from all HCV prevalence settings: high (>3.5%), 
moderate (1.5-3.5%), and low (<1%).12 I analyzed the distribution of HCV RNA at 
the time of diagnosis, and performed bivariate and multivariate analyses to 
identify demographic and clinical characteristics associated with having a low 
RNA at diagnosis and therefore being at risk for having a false negative POC test 
with a less-sensitive assay. My goal is to generate evidence to inform test 
development and implementation standards, and identify whether there are 
subpopulations of patients with HCV that may be missed by a less sensitive POC 
diagnostic test.  
 
 
III: Study questions: 
 
1- What is the distribution of HCV RNA at the time of diagnosis among those 
with chronic HCV infection? 
a. What is the clinical sensitivity of a test with an LOD of 3 log IU/ml? 
	  	  
5 
 
2- What patient or disease specific factors are associated with viral load 
below 3 log IU/mL thus increasing the likelihood of a false negative test? 
a. Does HIV co-infection significantly lower the HCV viral load? 
b. Is viral load lower among those with cirrhosis and poor hepatocyte 
capacity for HCV replication?  
 
 
IV: Study Objectives and Hypotheses: 
 
Objectives:  
1. To determine the distribution of hepatitis C virus (HCV) ribonucleic acid (RNA) 
levels among patients with chronic HCV infection in a global dataset 
representative of the six major HCV genotypes. 
2. To evaluate patient and disease specific factors associated with HCV RNA 
levels below 3 log IU/mL to identify subpopulations that may yield false negative 
results when implementing an HCV diagnostic test with lower analytic sensitivity. 
 
Hypothesis I:  
In cohorts of newly-diagnosed patients with chronic HCV from the countries of 
Cambodia, Cameroon, Canada, Georgia, Indonesia, Malaysia, Pakistan, 
Thailand, and Vietnam, 3% of subjects will have HCV RNA less than 1000 
international units per milliliter (IU/mL) (3 log10 IU/mL)  
Hypothesis II:  
HCV RNA < 3 log IU/mL will be associated with cirrhosis, but will not be 
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associated with age, sex, country, HCV genotype, or HIV co-infection. 
a. Primary exposures of interest: cirrhosis, HIV co-infection 
b. Primary outcome: low-level HCV viremia < 3 log IU/mL 
 
V: Methods:  
 
Study Design: This is a secondary analysis of cross-sectional data collected 
between January 1, 2007 and June 1, 2017 in the countries of Cambodia, 
Cameroon, Canada, Georgia, Indonesia, Malaysia, Pakistan, Thailand, and 
Vietnam. A flow diagram of the data sources including cohort type and number 
included is depicted in Figure 1.  
 
q Study population:  Males and females of all ages with positive 
quantitative HCV RNA were eligible to be included 
  
§ Inclusion: This study will include males and females of all ages with 
detectable quantitative HCV RNA measured by polymerase chain 
reaction (PCR) in international units per milliliter (IU/mL) collected 
between January 1, 2007 and June 30, 2017. 
§ Exclusion: Participants without a detectable quantitative HCV RNA 
PCR result will be excluded.   
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q Data Sources: 
 
Cambodia and Pakistan 
The data for Cambodia and Pakistan are from treatment studies at 
Médecins Sans Frontières (MSF) clinic sites.  The Cambodia clinic site was 
established in collaboration with the Ministry of Health Preah Kossamak Hospital 
in Phnom Penh.  Patients are referred from the hospital to the MSF supported 
clinic where HCV testing and treatment started in May 2016.  Cambodia has 
moderate HCV prevalence, 2.3%, with the highest rates of infection among 
injection drug users (IDU).  
 In Karachi, Pakistan, MSF operates a primary health clinic in Machar 
Colony, one of the biggest slums in the city.  MSF initiated a Hepatitis C testing 
and treatment programme within the clinic in February 2015. Pakistan has high 
HCV prevalence, 5.3%, with the highest rates among IDU.  
Cameroon 
The Institut Pasteur in Yaoundé, Cameroon contributed data for 3,155 
individuals with detectable HCV RNA from a selected cohort of those with HCV 
testing documented in a clinical database.  The seroprevalence in Cameroon is 
low, < 1.1%, with persons born between 1945-1965 most affected, predominantly 
via iatrogenic transmission.   
Canada 
The Canadian data are from the British Columbia Hepatitis Testers 
Cohort, a dynamic cohort including all individuals who were tested for hepatitis C 
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or HIV, or diagnosed with, hepatitis B, hepatitis C, HIV or active tuberculosis 
since 1990 in British Columbia.  The cohort is managed by the British Columbia 
Center for Disease Control where all laboratory tests for the province are 
performed and thus all patients tested in the province are included in the dataset. 
There are no other inclusion or exclusion criteria. Canada has low HCV 
prevalence of 0.8%. While the majority of incident infections occur among IDU, 
prevalent disease was predominantly acquired via IDU and iatrogenic 
(transfusions) with a small percentage with unknown transmission risk.    
Indonesia, Malaysia, Thailand, and Vietnam  
The data from Indonesia, Malaysia, Thailand, and Vietnam are a subset of 
the Therapeutics Research, Education, and AIDS Training in Asia (TREAT Asia) 
observational database.  The overall database includes data from an 
observational cohort study of patients with HIV at 21 sites in 12 countries 
throughout the Asia-Pacific region. Demographic, clinical and treatment data are 
aggregated twice each year via electronic data transfer. A subset of those with 
HCV co-infection who have completed HCV treatment will be included in this 
analysis using a cross-section of data from the time of HCV diagnosis. HCV 
prevalence in these regions is moderate, 2.2%, with the majority of infections 
acquired from IDU. 
Georgia 
 
The Georgia HCV Elimination Program 13,14, an initiative launched by a 
partnership between the Georgia Ministry of Health, US Centers for Disease 
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Control, and Gilead Sciences, contributed data for 29,568 individuals tested 
between April 2015 and May 2017.  Georgia is among the highest HCV 
prevalence in the world at 7.7% with the majority of incident infections among 
IDU, though iatrogenic transmission with unsafe injection practices and 
transfusions continues.   
 
VI: Data Concatenation  
I developed a protocol for data concatenation defining all covariates of 
interest. I outlined categories and associated dummy variables for all categorical 
variables (age, sex, country, HCV genotype, cirrhosis). All units were converted 
to the international system of units. Presence or absence of cirrhosis was 
determined from either from FibroScan® results reported in Metavir stage, or 
calculated from Fibrosis- 4 score 15,16 when FibroScan® results were not 
available as Fibrosis- 4 scores correlate well with FibroScan® to estimate fibrosis 
17-19. Those with Metavir stage F4 were considered to have cirrhosis while all 
others without cirrhosis. Those with a Fibrosis-4 score > 3.25 were also coded as 
cirrhosis.  In the Canadian dataset, presence or absence of cirrhosis was 
determined from diagnostic codes similar to US ICD 10 codes.   
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Figure 1.  Flow diagram depicting data sources that contributed to the global 
dataset with cohort type and number of participants included.  
 
 
 
 
VII: Statistical Methods 
 
I employed descriptive statistics to derive the HCV viral load distribution in 
log10 IU/mL for baseline HCV RNA among all patients in the combined dataset. 
From this distribution, I identified the corresponding percentile for 3 log IU/mL to 
estimate the clinical sensitivity.   
To test the association of HIV co-infection with HCV viremia < 3 log IU/mL, 
I performed a subset analysis of complete cases containing HIV testing results 
(positive or negative).  I first performed bivariate analyses among this subset to 
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investigate the odds of HCV RNA < 3 log IU/mL. For the categorical variable of 
HCV genotype, this was done using the chi-square statistic with an alpha of 0.05. 
Logistic regression was performed for the remaining dichotomous variables.  
Next, I performed multivariate analysis to investigate potential confounding of 
HIV co-infection on the association of cirrhosis with low-level HCV viremia  
I then returned to the complete dataset.  To test for additional co-factors 
associated with HCV RNA below 3 log IU/mL (and hence a higher likelihood of a 
false negative POC test), I calculated summary statistics for all covariates of 
interest and tested associations between each covariate and the odds of having 
HCV RNA < 3 log IU/mL. For categorical variables this was done using the chi-
square statistic.  I then sequentially added covariates to assess for confounding, 
and constructed multivariate logistic regression model of the odds of having HCV 
RNA < 3 log IU/mL. Variables were retained in the final model if they met the 
10% rule of change in the crude measure (OR) compared to the adjusted 
measure (aOR) of the association between the main exposure (cirrhosis) and the 
primary outcome (low-level HCV viremia < 3 log IU/mL).  
Outcome and Measurements 
q Demographic 
• Age 
• Sex 
• Country of study site 
q Clinical 
• HIV status 
• Presence or absence of cirrhosis  
• HCV RNA quantification (log IU/ml) 
• HCV Genotype 
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VIII: Results: 
 
Objective 1: 
 
I combined data from the countries of Cambodia Canada, Cameroon, 
Georgia, Indonesia, Malaysia, Pakistan, Thailand, and Vietnam to generate a 
convenience dataset of 53,295 individuals with chronic HCV infection (Figure 1).  
Médecins Sans Frontières (MSF) contributed data for 1553 participants 
referred to an HCV testing and treatment clinic in Cambodia and 155 participants 
evaluated at a primary health clinic located in Machar Colony, one of the biggest 
slums in Karachi, Pakistan. The Institut Pasteur in Yaoundé, Cameroon 
contributed data for 293 individuals from a selected cohort of those with HCV 
testing documented in a clinical database. The British Columbia Centre for 
Disease Control Hepatitis C Testers Cohort, a cohort that includes data for all 
individuals tested for HCV or HIV in the province of British Columbia 20, 
contributed HCV viral load testing results and genotypes for 21,794 individuals 
who tested positive for HCV RNA between January 2007 and December 2016. 
The Georgia HCV Elimination Program 13,14, an initiative launched by a 
partnership between the Georgia Ministry of Health, US Centers for Disease 
Control, and Gilead Sciences, contributed data for 29,129 individuals tested 
between April 2015 and May 2017. The TREAT Asia cohort 21,22 included 371 
HIV/HCV co-infected injection drug users (IDU) enrolled from Indonesia, 
Malaysia, Thailand, and Vietnam.  
Characteristics for the combined dataset are presented in Table 1. 
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Females comprised 24.65% (13.139) of participants with a median age of 49 
years. HIV co-infection occurred in 3% (1597) with 58.4% (31,131) of the cohort 
missing HIV testing data. The genotype distribution was: 50.94% (27,148) 
genotype 1, 17.4% (9,271) genotype 2, 27.93% (14,886) genotype 3, 1.81% 
(966) genotype 4, < 1% (13) genotype 5, 1.57% (841) genotype 6, and < 1% 
(170) with mixed genotype.  Cirrhosis was present in 10.98% (5,850).   
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Table 1. Characteristics of participants with chronic hepatitis C virus (HCV) in a 
global database assembled from cohorts and laboratory data in the countries of 
Cambodia, Canada, Cameroon, Georgia, Indonesia, Malaysia, Pakistan, 
Thailand, and Vietnam. 
Characteristics Total Cohort 
N (Col %) 
Age 
≤ 30 years 
> 30 years 
Mean (Range) 
 
2793 (5.24) 
50,502 (94.76) 
49.10 (0 – 98) 
Sex 
Female 
Male 
 
13,139 (24.65) 
 40,156 (75.35) 
Country 
Cambodia 
Cameroon 
Canada 
Georgia 
Indonesia 
Malaysia 
Pakistan 
Thailand 
Vietnam 
 
1553 (2.91) 
293 (0.55) 
21,794 (40.89) 
29,129 (54.66) 
133 (0.25) 
24 (0.05) 
155 (0.29) 
123 (0.22) 
91 (0.17) 
Characteristics Total Cohort 
N (Col %) 
HIV  
Co-Infected 
Negative 
Missing Data 
 
1597 (2.99) 
20,567 (38.59) 
31,131 (58.4) 
HCV Genotype 
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4 
Genotype 5 
Genotype 6 
Mixed 
 
27,148 (50.94) 
9,271 (17.40) 
14,886 (27.93) 
966 (1.81) 
13 (0.02) 
841 (1.57) 
170 (0.32) 
Cirrhosis 
Yes 
No 
 
5,850 (10.98) 
47,447 (89.02) 
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HCV Viral Load Distribution  
 
The HCV RNA (log IU/mL) frequency distribution for the combined dataset 
is depicted in Figure 2. The 3 log IU/mL threshold corresponded to the 98th 
percentile in the dataset.  Markers for the 99th and 97th percentiles with 
corresponding viremia values were derived for reference and correspond to 2.61 
log IU/mL and 3.29 log IU/mL respectively.  
 
Figure 2.  Frequency distribution of HCV RNA (log10 IU/mL) with threshold values 
for the 99th, 97th, and 95th percentiles among 53,293 participants with hepatitis C 
viremia in a global dataset. 
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Results – Objective 2:   
 
Hypothesis 2a: 
 The proportion of the total dataset missing HIV results was 58.4% 
(31,131).  The participants with HIV data are presented by country in addendum 
Table A1, where only Canada contained informative HIV-infected and uninfected 
results. Among this subset of Canadian data, bivariate analyses for the 
association of covariates, with low-level HCV viremia below 3 log IU/mL found 
age ≤ 30 years had 3.70 times the odds for low-level viremia compared to those 
> 30 years (95% CI 2.92, 4.69) (Table 2).  Females were also 1.65 times more 
likely to have low-level viremia compared to men (95% CI 1.37, 1.99). HCV 
genotype was not significant with a p value of 0.33.  Those with cirrhosis had 
increased odds of 1.37 (95% CI 1.12, 1.69), while HIV was not significant with an 
OR of 1.22 (95% CI 0.85, 1.77). 
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Table 2. Bivariate analyses for association of characteristics (exposure) with low-
level HCV viremia below 3 log IU/mL (outcome) among 21,794 participants with 
complete HIV data in Canada.  
Characteristics Total Cohort 
N (Col %) 
Low-Level Viremia 
N (Row %) 
OR  
(95%CI) 
Age 
≤ 30 years 
> 30 years 
 
1324 (6.21) 
20,012 (93.79) 
 
90 (6.36) 
368 (1.81) 
 
3.70 (2.92, 4.69) 
Sex 
Female 
Male 
 
6,932 (32.49) 
14,404 (67.51) 
 
203 (2.85) 
255 (1.74) 
 
1.65 (1.37, 1.99) 
HCV Genotype 
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4-6 
 
14,410 (67.54) 
1839 (8.62) 
4,657 (21.83) 
430 (2.02) 
 
293 (1.99) 
29 (2.08) 
116 (2.43) 
10 (2.18) 
 
P value 0.33 
 DF = 3 
Cirrhosis 
Yes 
No 
 
4913 (22.54) 
16,881 (77.46) 
 
130 (2.65) 
328 (1.94) 
 
1.37 (1.12, 1.69) 
REF 
HIV  
Co-Infected 
Negative 
 
1227 (5.63) 
20567(94.37) 
 
31(2.53) 
427(2.08) 
 
1.22 (0.85, 1.77) 
REF 
DF = degrees of freedom 
Multivariate analyses adding HIV co-infection to cirrhosis for the 
association with low-level HCV viremia yielded the same OR for cirrhosis of 1.37 
(95% CI 1.12, 1.68), thus representing 0% change (Table 3). I then added age 
and sex covariates sequentially to HIV and cirrhosis (primary exposures of 
interest) (addendum Tables A2-A3).  Again, % change in the primary exposure of 
interest were < 10%.  
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Table 3. Multivariate analyses for association of HIV and cirrhosis with low-level 
HCV viremia below 3 log IU/mL among 21,794 participants with complete HIV 
data in Canada. 
Characteristics  Bivariate OR  
(95%CI) 
Multivariate OR 
(95% CI) 
% Change 
Cirrhosis 
Yes 
No 
 
1.37(1.12, 1.69) 
REF 
 
1.37 (1.12, 1.68) 
 
0% 
HIV  
Co-Infected 
Negative 
 
1.22 (0.85, 1.77) 
REF 
 
1.21 (0.84, 1.75) 
 
 
 
 
 
Hypothesis 2b: 
HCV RNA in the total combined dataset was then divided into a 
dichotomous outcome: greater or equal to 3.0 log IU/mL, and low-level viremia 
less than 3.0 log IU/mL. HIV was not retained in the model, and the full database 
was explored to identify any other risk factors or confounders.  Bivariate analyses 
for the association of remaining characteristics with odds of low-level viremia 
found increased OR of 2.47 (95% CI 2.04, 2.99) for those ≤ 30 years of age 
compared to those > 30 years (Table 4). Females also had increased odds of 
1.17 (95% CI 1.02, 1.34).  For the categorical variable of country of study site, 
the chi-square p-value was 0.005 with 4 degrees of freedom.  The significant 
difference between countries, however, was driven by decreased likelihood of 
low-level viremia, thus countries were not significantly associated with low-level 
viremia.  HCV genotype and cirrhosis were not significantly associated with low-
level viremia. 
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Table 4. Bivariate analyses for association of characteristics (exposure) with low-
level HCV viremia below 3 log IU/mL (outcome) in a global dataset with 53,295 
participants. Significant OR or p-value from Chi-square test in bold.  
Characteristics Total Cohort 
N (Col %) 
Low-Level Viremia 
N (Row %) 
OR  
(95%CI) 
Age 
≤ 30 years 
> 30 years 
 
2793 (5.24) 
50,502 (94.76) 
 
125 (4.48) 
939 (1.86) 
 
2.47 (2.04, 2.99) 
REF 
Sex 
Female 
Male 
 
13,136 (24.65) 
 40,157 (75.35) 
 
294 (2.24) 
770 (1.92) 
 
1.17(1.02, 1.34) 
REF 
Country 
Cambodia 
Cameroon 
Canada 
Georgia 
Asia, Other 
 
1544 (2.90) 
293 (0.55) 
21,794 (40.89) 
29,129 (54.66) 
523 (1.00) 
 
13 (0.84) 
2 (0.68) 
458 (2.10) 
588 (2.02) 
3 (0.57) 
 
P value = 0.005 
DF = 4 
HCV Genotype 
Genotype 1 
Genotype 2 
Genotype 3 
Genotype 4-6 
 
27,148 (50.94) 
9,271 (17.40) 
14,886 (27.93) 
1990 (3.73) 
 
511 (1.88) 
203  (2.19) 
320 (2.15) 
30 (1.51) 
 
P value = 0.051 
DF = 3  
Cirrhosis 
Yes 
No 
 
5,846(10.97) 
47,447(89.03) 
 
135 (2.31) 
929 (1.96) 
 
1.18 (0.99, 1.42) 
REF 
 
  
 I then performed stepwise multivariate logistic regression analyses to build 
my final model.  First, I added covariates sequentially to cirrhosis (primary 
exposure of interested) (addendum Tables A4-A14), entering those with the 
largest bivariate OR first.  No covariates met the 10% rule of change.  Lastly, 
given the significant OR found for age in the bivariate analyses, I added 
covariates sequentially to age (addendum Tables A15-24). No covariates met the 
10% rule of change.   
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Results Conclusions: 
 
In this cross-sectional analysis of HCV testing data from around the globe, 
a test with a 3 log IU/mL limit of detection will correctly diagnose 98% of patients 
with chronic HCV infection.  In a subset analysis of those with HIV testing data, 
HIV co-infection was not significantly associated with low-level viremia < 3 log 
IU/mL, and did not confound the association of cirrhosis with low-level viremia.  
In bivariate analyses of the complete dataset, age less than or equal to 30 years 
had 2.47 times the odds for low-level viremia compared to those over 30 years 
old, and females were slightly more likely to have low-level viremia with an OR of 
1.17.  Country and HCV genotype were not significantly associated with low-level 
viremia suggesting that regional differences in HCV epidemiology are unlikely to 
affect test performance.  Additionally, the presence of cirrhosis was not 
significantly associated with low-level viremia.  Among the covariates assessed, 
there was no significant confounding of the associations of cirrhosis with low-
level viremia or age with low-level viremia.   
 
IX: Strengths and Limitations 
 
Weaknesses/Limitations: 
 
This is a secondary analysis of data collected from differing sites around 
the globe with different intentions and methods for data collection.  Some data 
were collected as part of research protocols with strict inclusion and exclusion 
criteria (TREAT Asia), while others represent a broad sample of tests performed 
in the general population at a reference laboratory (Canada). This introduces 
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bias as the study population is one of convenience, which thus limits 
generalizability of the conclusions.  The subset analysis for HIV was further 
restricted to only one country where HIV positive and negative results were 
available. Measures of HIV control and treatment were not available and could 
not be controlled for in the analysis.  Further grouping of countries with < 200 
individual data points and genotypes 4-6 creates a mild loss of precision.  Lastly, 
the cross-sectional design provides only one measurement of HCV RNA per 
individual and thus associations of HCV RNA with patient and disease factors 
cannot be evaluated over time and causal inference cannot be deduced.  
 
Strengths: 
 
 The large sample size for this study provided more than adequate power 
to investigate the covariates of interest.  The broad global distribution allowed for 
comparison of the potential impact of regional HCV epidemiology, and regions 
with the highest HCV prevalence were well represented as well as low 
prevalence settings as a comparator.   
 
X: Importance and Future Directions: 
 
This study investigated the viral load distribution among those with chronic 
HCV infection from around the globe to estimate the clinical sensitivity of a point-
of-care test for HCV diagnosis and inform sub-populations that may be at risk for 
false negative testing.  The findings suggest that a test with a limit of detection of 
3 log IU/mL, 100 times higher (less sensitive) than the gold standard assay will 
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likely detect 98% of chronic HCV infection worldwide.  My results suggest that 
such a test would perform well among most population subgroups, with the 
exception of persons  <30 years of age. Among such patients, who are more 
likely to have recent infection with wider fluctuation in viremia, the odds of a false 
negative test are higher and may require repeat testing at a later date. A 
prequalification criterion for an HCV POC test to have a limit of detection = 3 log 
IU/mL could facilitate affordable product development, and expand the reach of 
HCV testing in resource-limited settings.  To investigate which settings may 
benefit the most from POC testing, comparative and cost-effectiveness analyses 
will be needed.   
 
XI: Role in the study:  
J. Morgan Freiman, MD.  I am currently an Assistant Professor of Medicine in the 
Department of Internal Medicine, Section of Infectious Diseases, and an 
Infectious Diseases physician at Boston Medical Center and Whittier Street 
Health Center.  I developed this study concept and design.  I performed a 
comprehensive literature review to formulate the study question and address key 
gaps in current evidence. With the assistance of my mentors and advisors, I 
secured the data sources for this study. A data analyst assisted with data 
concatenation. I performed all additional statistical analyses as outlined above. I 
presented the results orally to the thesis committee, and prepared this written 
thesis document. 
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Addendum 
 
Table A1. Participants with HIV infection presented by country 
 
Country HIV Infected 
(Row %) 
HIV Uninfected 
(Row %) 
Missing 
Row (%) 
Cambodia 0 0 1553(100%) 
Cameroon 0 0 293(100%) 
Canada 1227(5.63%) 20,567(94.37%) 0 
Georgia 0 0 29,129(100%) 
Indonesia 133(100%) 0 0 
Malaysia 24(100%) 0 0 
Pakistan 0 0 155(100%) 
Thailand 123(100%) 0 0 
Vietnam 90(100%) 0 0 
 
 
Table A2. Multivariate analyses for association HIV, cirrhosis, and age with low-
level HCV viremia below 3 log IU/mL among 21,794 participants with complete 
HIV data in Canada. 
Characteristics  Bivariate OR  
(95%CI) 
Multivariate OR 
(95% CI) 
% Change 
Cirrhosis 
Yes 
No 
 
1.37(1.12, 1.69) 
REF 
 
1.30 (1.06, 1.60) 
 
5% 
HIV  
Co-Infected 
Negative 
 
1.22 (0.85, 1.77) 
REF 
 
1.23 (0.85, 1.77) 
 
 
 
Age 
≤ 30 years 
> 30 years 
 
3.70 (2.92, 4.69) 
 
3.63 (2.87, 4.61) 
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Table A3. Multivariate analyses for association HIV, cirrhosis, and sex with low-
level HCV viremia below 3 log IU/mL among 21,794 participants with complete 
HIV data in Canada. 
Characteristics  Bivariate OR  
(95%CI) 
Multivariate OR 
(95% CI) 
% Change 
Cirrhosis 
Yes 
No 
 
1.37(1.12, 1.69) 
REF 
 
1.35 (1.10, 1.66) 
 
1.45% 
HIV  
Co-Infected 
Negative 
 
1.22 (0.85, 1.77) 
REF 
 
1.23 (0.86, 1.80) 
 
 
 
Sex 
Female 
Male 
 
3.70 (2.92, 4.69) 
 
3.63 (2.87, 4.61) 
 
 
 
Table A4. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and age.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.15 (0.96, 1.38) 
REF 
 
2.54% 
 
 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.46 (2.03, 2.98) 
REF 
  
No 
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Table A5. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and sex.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.16 (0.97, 1.40) 
REF 
 
1.69% 
 
 
Sex 
Female 
Male 
 
1.17(1.02, 1.34) 
REF 
 
1.16 (1.01, 1.33) 
REF 
  
No 
 
 
 
Table A6. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and Cambodia.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.24 (1.04, 1.49) 
 
5% 
 
 
Country 
Cambodia 
Other 
 
0.39 (0.23, 0.68) 
 
 
0.38 (0.22, 0.67) 
REF 
  
No 
 
 
Table A7. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and Cameroon. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.18 (0.98, 1.41) 
 
0% 
 
 
Country 
Cameroon 
Other 
 
0.32 (0.08,1.29) 
 
 
0.34 (0.09, 1.38) 
  
No 
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Table A8. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and Canada. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.15 (0.95, 1.39) 
 
2.54% 
 
 
Country 
Canada 
Other 
 
 
 
1.06 (0.94, 1.21) 
  
No 
 
 
Table A9. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and Georgia. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.25 (1.02, 1.52) 
 
5.9% 
 
 
Country 
Georgia 
Other 
 
0. 96 (0.85, 1.09) 
 
 
1.06 (0.94, 1.21) 
  
No 
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Table A10. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and the combined 
data for the countries of Indonesia, Malaysia, Pakistan, Thailand, and Vietnam. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.24 (1.03, 1.49) 
 
5.1% 
 
 
Country 
Asia, Other 
Other 
 
0.27 (0.09, 0.83) 
 
1.06 (0.94, 1.21) 
  
No 
 
 
 
Table A11. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and genotype 1.  
 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% 
Change 
Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.21(1.01, 1.45) 
REF 
 
2.5% 
 
 
HCV Genotype 
Genotype 1 
Other 
 
 
REF 
   
No 
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Table A12. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and genotype 2.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% 
Change 
Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.20 (1.0, 1.44) 
REF 
 
1.7% 
 
 
HCV Genotype 
Genotype 2 
Other 
 
 
REF 
 
1.14 (0.97, 1.33) 
  
No 
 
 
 
Table A13. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and genotype 3.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% 
Change 
Retain? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.20 (1.0, 1.44) 
REF 
 
1.7% 
 
 
HCV Genotype 
Genotype 3 
Other 
 
 
REF 
 
1.12 (0.98, 1.28) 
  
No 
 
 
Table A14. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for cirrhosis and genotypes 4-6.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain
? 
Cirrhosis 
Yes 
No 
 
1.18 (0.99, 1.42) 
REF 
 
1.19 (0.99, 1.43) 
REF 
 
<1% 
 
 
HCV Genotype 
Genotype 4-6 
Other 
 
 
REF 
 
0.73 (0.51, 1.06) 
  
No 
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Table A15. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and sex.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.44 (2.02, 2.96) 
REF 
  
 
Sex 
Female 
Male 
 
 
REF 
 
1.13 (0.98, 1.29) 
  
No 
 
 
 
Table A16. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and the country of 
Cambodia.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.45 (2.03, 2.97) 
REF 
  
 
Country 
Cambodia 
Other 
 
 
REF 
0.42 (0.24, 0.73)   
No 
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Table A17. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and the country of 
Cameroon.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.47 (2.04, 2.98) 
REF 
 
0% 
 
 
Country 
Cameroon 
Other 
 
 
REF 
0.36 (0.09, 1.44)   
No 
 
 
 
Table A18. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and the country of 
Canada.  
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.46 (2.03, 2.97) 
REF 
 
0% 
 
 
Country 
Canada 
Other 
 
 
REF 
1.06 (0.94, 1.20)   
No 
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Table A19. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and the country of 
Georgia. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain
? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.48 (2.05, 3.01) 
REF 
 
0% 
 
 
Country 
Georgia 
Other 
 
 
REF 
1.05 (0.93, 1.19)   
No 
 
 
 
Table A20. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and the combined data 
for the countries of Indonesia, Malaysia Pakistan, Thailand, and Vietnam. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.47 (2.04, 2.99) 
REF 
 
0% 
 
 
Country 
Asia Other 
Other 
 
 
REF 
--   
No 
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Table A21. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and genotype 1. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.49 (2.06, 3.02) 
REF 
 
0% 
 
 
Genotype 
Genotype 1 
Other 
 
 
REF 
 
0.87 (0.77, 0.99) 
  
No 
 
 
 
Table A22. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and genotype 2. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.48 (2.05, 3.00) 
REF 
 
0% 
 
 
Genotype 
Genotype 2 
Other 
 
 
REF 
 
1.13 (0.97, 1.32) 
  
No 
 
 
 
Table A23. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and genotype 3. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.48 (2.05, 3.00) 
REF 
 
0% 
 
 
Genotype 
Genotype 3 
Other 
 
 
REF 
 
1.12 (0.98, 1.28) 
  
No 
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Table A24. Multivariate analysis for association of characteristics with low-level 
HCV viremia < 3 log IU/mL. OR adjusted (aOR) for age and genotypes 4, 5, 6, 
and mixed. 
Characteristic Bivariate OR  
(95%CI) 
aOR 
(95% CI) 
% Change Retain? 
Age 
≤ 30 years 
> 30 years 
 
2.47 (2.04, 2.99) 
REF 
 
2.47 (2.04, 2.98) 
REF 
 
0% 
 
 
Genotype 
Genotype 4-6 
Other 
 
 
REF 
 
0.76 (0.53, 1.10) 
  
No 
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